Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Wary Of These Three Collapsing Stocks

Synchronoss Technologies, Inc. (NASDAQ:SNCR), OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) and Cemtrex Inc (NASDAQ:CETX) are in the public eye today for the wrong reasons as their shares are seeing significant declines, as major indices lose 1%-to-1.8% in intraday trading. Nonetheless, it should be noted that we are going to discuss these three firms based on how hedge funds have been treating them in order to gain a more rounded understanding of whether they may be candidates for buying, holding, or selling. Tracking hedge fund activity, especially in nano- and small-cap stocks like those of Synchronoss Technologies, OncoGenex Pharmaceuticals, and Cemtrex can be a very powerful tool in the arsenal of the informed investor.

U.S. Financial Hub: Wall Street

U.S. Financial Hub: Wall Street

So let’s first analyze how tracking hedge funds can help an everyday investor. Through our research, we discovered that a portfolio of the 15 most popular small-cap picks of hedge funds beat the S&P500 Total Return Index by nearly a percentage point per month on average between 1999 and 2012. On the other hand, the most popular large-cap picks of hedge funds underperformed the same index by seven basis points per month during the same period. This is likely a surprise to many investors, who think of small-caps as risky, unpredictable stocks and put more faith in large-cap stocks. In forward tests since August 2012, these top small-cap stocks beat the market by an impressive 60.4 percentage points, returning 118% (read the details here). Hence, a retail investor needs to isolate himself from the herd and take advantage of the best growth opportunities in the market by concentrating on small-cap stocks.

Taking this into account, the first firm we will be looking at is Synchronoss Technologies, Inc. (NASDAQ:SNCR), the shares of which lost nearly 25% of their value before paring their losses down to just over 12%. The volatility and sharp decline follows a milder but still significant slide of over 4% yesterday. It should be noted that with its slump today, Synchronoss has hit a new low for 2015, and is down by 21.5% year-to-date.

Follow Synchronoss Technologies Inc (NASDAQ:SNCR)
Trade (NASDAQ:SNCR) Now!

Hedge funds that we track are not overly very keen on Synchronoss Technologies, Inc. (NASDAQ:SNCR) of late. Although there was an increase of three hedge funds with long positions in the stock during the second quarter to 21, their total investment in the company decreased by 3.19% to about $96.86 million. The stock declined by 3.65%, however, meaning there was a slight increase in hedge fund investment in the firm, but very minimal considering three new investors took up positions. Furthermore, only 4.90% of the firm’s outstanding shares are owned by hedge funds we follow, which is low for a small-cap stock. Brian Ashford-Russell and Tim Woolley’s Polar Capital held the largest stake in Synchronoss at the end of June among the funds we track, owning 1.09 million shares, down by 69% quarter-over-quarter.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.